SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
15 references·5 citing·43 second hop
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)Cost-Effectiveness Analysis of Regorafeni…First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis (2015)First- and Second-Line Bevaci…Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Updating Cost-Effectiveness —…Indication-Specific Pricing for Cancer Drugs (2014)Indication-Specific Pricing f…Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2013)Value‐Based Differential Pric…Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Consolidated Health Economic …Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Projections of the Cost of Ca…Improved curve fits to summary survival data: application to economic evaluation of health technologies (2011)Improved curve fits to summar…A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer (2011)A Trial-Based Assessment of t…Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial (2009)Prospective Cost-Effectivenes…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Limits on Medicare's Ability …An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard (2008)An Empiric Estimate of the Va…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment (2002)Health Economic Evaluations: …EQ-SD: a measure of health status from the EuroQol Group (2001)EQ-SD: a measure of health st…Willingness to Pay for a Quality-adjusted Life Year (2000)Willingness to Pay for a Qual…Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)Cost-effectiveness of Nivolum…Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis (2018)Regorafenib treatment for pat…Cost effectiveness of regorafenib as second‐line therapy for patients with advanced hepatocellular carcinoma (2017)Cost effectiveness of regoraf…Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma (2017)Cost Effectiveness of Nivolum…Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies (2015)Metastatic Colorectal Cancer:…Contingent Valuation: Is Some Number Better than No Number? (1994)Cost-Effectiveness in Health and Medicine (1996)Cost-of-illness studies: concepts, scopes, and methods (2014)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Social Security Bulletin (2018)Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)Decision Modelling For Health Economic Evaluation (2006)Practical methods for incorporating summary time-to-event data into meta-analysis (2007)Overview of Parametric Survival Analysis for Health-Economic Applications (2013)First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma (2019)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)Quality of life and pharmacoeconomics in clinical trials (1996)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)The price of innovation: new estimates of drug development costs (2003)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Five Years of Cancer Drug Approvals (2015)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (2022)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)An economic evaluation of the war on cancer (2010)EuroQol - a new facility for the measurement of health-related quality of life (1990)EuroQol: the current state of play (1996)Depression, chronic diseases, and decrements in health: results from the World Health Surveys (2007)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) (2011)Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets (2012)Delivering affordable cancer care in high-income countries (2011)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Medical Care Costs Associated with Cancer Survivorship in the United States (2020)Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review (2018)Economics and mental health: the current scenario (2020)Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Medicare and Cost-Effectiveness Analysis (2005)Recommendations of the Advisory Committee on Immunization Practices (ACIP) (2008)
this work references cited by second hop

References

  • 2001EQ-SD: a measure of health status from the EuroQol Group5,610 cited
  • 2011Projections of the Cost of Cancer Care in the United States: 2010-20202,653 cited
  • 2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,247 cited
  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force1,997 cited
  • 2000Willingness to Pay for a Quality-adjusted Life Year849 cited
  • 2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs391 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2002Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment340 cited
  • 2011Improved curve fits to summary survival data: application to economic evaluation of health technologies308 cited
  • 2008An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard196 cited
  • 2015First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis157 cited
  • 2013Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context142 cited
  • 2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

139 cited
  • 2014Indication-Specific Pricing for Cancer Drugs128 cited
  • 2011A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer113 cited
  • Cited by

    • 2017Cost effectiveness of regorafenib as second‐line therapy for patients with advanced hepatocellular carcinoma84 cited
    • 2015Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies82 cited
    • 2021Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer68 cited
    • 2017Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma66 cited
    • 2018Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis55 cited